 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > CytRx Corporation
 |
CytRx Corporation |
 |
 |
 |
PROFILE |
 |
CytRx (pronounced "sci-trex") treks through the depths of science to develop critical-care pharmaceuticals. The company's lead drug candidate is FLOCOR, which enhances blood flow, may relieve the pain of acute sickle cell anemia. Studies suggest it could also help treat vascular disorders such as stroke and heart attacks. CytRx is also developing possible therapies for muscular dystrophy, spinal cord injuries, and cancer. Its other technologies include Optivax, a vaccine-enhancing technology, and TRANZFECT, a DNA-based vaccine delivery technology, which it has licensed to Merck. The firm has licensed a technology promoting growth in animals raised for food to Ivy Animal Health.
COMPETITION |
 |
Bristol-Myers Squibb Company (BMY)
Questcor Pharmaceuticals, Inc. (QSC)
SuperGen, Inc. (SUPG)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 3.30
1-Yr. Sales Growth: 316.0%
KEY PEOPLE |
 |
Jack J. Luchese
CEO
Mark W. Reynolds
CFO
CONTACT INFO |
 |
154 Technology Pkwy.
Norcross, GA 30092
US
Phone: 770-368-9500
Fax: 770-368-0622
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |